secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2023-04-28T23:59:59+00:00
Accession:  0001564590-23-006600
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Sana Biotechnology announces departure of Sunil Agarwal as EVP, Head of Development and CMO
--------------------------------------------------------------------------------

- Separation effective April 28, 2023; Sunil Agarwal to provide transition services under a Transition Agreement.
- Severance of $560,523 (9 months base salary plus pro-rata bonus) plus COBRA coverage for up to 9 months.
- Acceleration of 89,377 unvested stock options; exercise period extended to December 31, 2023.
- Consulting Agreement at $256/hour, effective April 29, 2023, ending May 12 or extended to May 26, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000156459023006600/0001564590-23-006600-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000156459023006600/sana-8k_20230428.htm
  HTML page:      https://secwatch.observer/filing/0001564590-23-006600

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer